# Pembrolizumab

## KEYTRUDA inj 100mg/4mL

##### 臨採

| TAH Drug Code      | [IKEY1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IKEY1){:target="_blank"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Biliary tract cancer, bladder cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, esophagogastric cancer, gastric cancer, head and neck cancer, hodgkin's disease, liver carcinoma, melanoma, merkel cell carcinoma, non-small cell lung cancer, nonsquamous non-small cell lung cancer, primary mediastinal (thymic) large b-cell lymphoma, renal cell carcinoma, solid tumor, squamous cell carcinoma of skin, squamous non-small cell lung cancer, triple-negative breast cancer, urothelial carcinoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Dosing             | [Melanoma] 2 mg/kg infused over 30 minutes once every 3 weeks until disease progression or unacceptable toxicity. [Non-Small Cell Lung Cancer (NSCLC)] 200 mg for untreated patients or 2 mg/kg as a single agent for previously treated patients infused over 30 minutes once every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months. [Classical Hodgkin Lymphoma (cHL), Head and Neck Squamous Cell Cancer (HNSCC), Urothelial Carcinoma] 200 mg infused over 30 minutes once every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity to pembrolizumab or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Common: Hypertension (24-67%), Alopecia (34-61%), Pruritus (11-41%), Rash (1.4-71%), Hypercholesterolemia (Non-small cell lung cancer, 20%), Hyperglycemia (40-48%), Hypertriglyceridemia (23-25%), Hypoalbuminemia (32-34%), Hyponatremia (10-38%), Weight decreased (10-34%), Constipation (12-42%), Decrease in appetite (16-44%), Diarrhea (12-62%), Nausea (11-67%), Leukopenia (24%), Thrombocytopenia (35%), Alkaline phosphatase above reference range (Non-small cell lung cancer, 26%), Aspartate aminotransferase serum level above reference range (20-24%), Arthralgia (10-31%), Disorder of musculoskeletal system (53-58%), Musculoskeletal pain (16-41%), Neuropathy (1-67%), Proteinuria (29-30%), Urinary tract infectious disease (11-32%), Cough (11-26%), Dyspnea (10-23%), Fatigue (20-70%). Serious: Myocardial infarction (Serious: 2%), Myocardial ischemia (2%), Myocarditis (0.5-1.4%), Pericarditis (4%), Right ventricular dysfunction, Vasculitis, Vasculitis, Drug reaction with eosinophilia and systemic symptoms, Hand-foot syndrome due to cytotoxic therapy (23-28%), Stevens-Johnson syndrome, Stevens Johnson syndrome AND toxic epidermal necrolysis overlap, Toxic epidermal necrolysis, Adrenal insufficiency (0.8%), Hyperthyroidism (3-12%), Hypoparathyroidism, Hypophysitis (0.6%), Hypothyroidism (8-67%), Thyroiditis (0.6-2%), Type 1 diabetes mellitus (0.2%), Colitis (1.7%), Duodenitis, Gastritis, Gastrointestinal obstruction, Malignant, Gastrointestinal perforation, Lower gastrointestinal hemorrhage, Pancreatitis, Anemia, Grade 3 or 4 (2-8%), Aplastic anemia, Febrile neutropenia (1.4%), Hemolytic anemia, Hemophagocytic lymphohistiocytosis, Hemorrhage (19-27%), Immune thrombocytopenia, Venous thromboembolism, Hepatitis (0.7-2.9%), Hepatotoxicity (14-39%), Veno-occlusive disease of the liver (9%), Anaphylaxis, Graft versus host disease (26%), Histiocytic necrotizing lymphadenitis, Hypersensitivity reaction (4.1%), Sarcoidosis, Systemic inflammatory response syndrome, Transplanted organ rejection, Vogt-Koyanagi-Harada disease, Eaton-Lambert syndrome, Myasthenia gravis (2.5%), Myositis (1-3.3%), Polymyalgia rheumatica, Polymyositis, Rhabdomyolysis, Confusional state (Head and neck cancer, 2% or more), Demyelination of spinal cord, Encephalitis, Guillain-Barre syndrome, Meningitis, Myelitis (0.5%), Nerve palsy, Iritis, Myasthenia gravis, Ocular, Optic neuritis, Uveitis (Up to 1.4%), Visual impairment, Acute renal failure (13-21%), Nephritis, Renal failure, Sepsis due to urinary tract infection, Pleural effusion (2% or more), Pneumonia (2% or more), Pneumonitis (2-11%), Pulmonary embolism (2%), Pulmonary hemorrhage, Respiratory failure (2% or more), Cardiorespiratory arrest, Disorder characterized by fever, Steroid-requiring, Fever (10-28%), Infusion reaction (0.2%), Infusion reaction (0.2-9%), Multiple organ failure, Sepsis (Up to 10%) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data – Potential Toxicity(Mother)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| More Info          | [UpToDate](https://www.uptodate.com/contents/pembrolizumab-drug-information){:target="_blank"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

